entertainment -WSS

entertainment

author：focus 2025-09-30 23:20:06 - browse：12562

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.

The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout LOUD podcast: live from JPM 2024

focus

WSS

Scientists uncover potential path to treating deadly childhood tumor

Researchers test human milk's ability to repair gut microbiome

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Doulas covered by Medicaid under New York's new plan

People with mental disorders often marry others with same

focus

entertainment

focus

Medical leaders decry Supreme Court decision on affirmative action

First Opinion on colorectal cancer screening: letter and response

Guidelines to prevent youth baseball injuries need more muscle

Health and fitness trackers are measuring the wrong things

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. decision on ALS drug has neurologists, advocates up in arms

At least 13 dead in Texas as scorching temps continue

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Cancer drug shortages should be causing more outrage

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

Drug companies' payments and gifts affect physicians' prescribing

Heart disease and mental health: A look at cardiac psychology

Pancreatic cancer is often deadly, but new discoveries are raising hope

The nurse manager staffing crisis is hurting patients

Republican states more likely to report Covid vaccine side effects

Bird flu in dairy cattle: New measures to control spread to humans

explore

entertainment

focus

leisure time